Evolent Health reaffirms FY2022 revenue and Adjusted EBITDA guidance at J.P. Morgan conference

Evolent Health, Inc.

Reaffirmed previously issued revenue and Adjusted EBITDA guidance for full year 2022.
Presenting at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.
Guidance based on preliminary, unaudited financials; actual results may differ materially.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).

Period: the year ended December 31, 2022
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

In connection with this presentation and investor meetings, the Company is reaffirming previously issued revenue and Adjusted EBITDA guidance for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.